Health Condition 1: null- Reducing hair loss, to increase hair growth and to improve scalp conditions in the androgenic alopecia.
Conditions
Interventions
Intervention1: Micronutrients Lotion and Tablet: Gently massage the lotion (around 4ml- 5ml with the help of a dropper) on entire scalp every night,
Take two tablets by mouth each day with main meal.
Sponsors
Meyer Organics Pvt Ltd Thane
Eligibility
Inclusion criteria
Inclusion criteria: Men aged 18 to 49 years with mild to moderate signs of AGA, which is classified in Modified Norwood-Hamilton Scale as stage 3V, 4 and 5. Not be on a course of treatment, which affects the outcome of the study. Individuals who are willing to give informed consent and willing to follow up. No topical treatment for AGA for at least 6 weeks and no systemic treatment for at least 3 months prior to study initiation. Willing to refrain from other AGA treatments during the course of the study. Not have had hair chemically treated (including colored hair, permed hair, etc) within the month prior to the study.
Exclusion criteria
Exclusion criteria: Coexistent androgenetic alopecia other than 3V, 4 and 5 stages of Norwood-Hamilton scale Unwilling to maintain a consistent hair style and to avoid shaving of scalp hair throughout the course of the study. Unable to comply with the protocol. Patients who are on chronic oral steroids are not eligible for the study Allergies to Investigational product. Presence of irritated or visibly inflamed scalp. Use of ultraviolet radiation, including tanning beds and PUVA therapy for treatment of acne, psoriasis, or any other skin condition within 2 months prior to study initiation. Evidence of immunocompromise. Advanced or poorly controlled diabetes. Unstable cardiovascular disease. Clinically significant medical or psychiatric disease as determined by the investigator. Local infection (e.g. cellulitis, abscess) or systemic infection (e.g. pneumonia, septicemia) within 3 months prior to the first dose of investigational drug. Those who have donated blood within a month of date of screening evaluation. Drug or alcohol abuse.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Outcome Measures Hair count by PTG (Phototrichograms)Timepoint: At baseline, 2,4 and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary Outcome Measures 1.Self assessment by Patients 2.Physical examination of scalp 3.Hair density rating scale 4.Global assessment by investigator 5.Compliance and adverse effects Timepoint: 1.after 2 and 4 months 2.at baseline, after 1, 2, 3 and 4 months 3.after 2 and 4 months 4.After treatment completion 5.Compliance and adverse effects | — |
Countries
India
Contacts
Public ContactDr Himanshu Tayade
Outcome results
None listed